Refractive Surgery News

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Ronald R. Krueger, MD, MSE, discusses a stable post-LASIK patient who was unhappy with image quality.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Mark A. Kontos, MD, compares allowing a patient time to heal vs. enhancing after small incision lenticule extraction.

A guest editorial published in the Journal of Cataract & Refractive Surgery provided updated criteria for collecting, analyzing and reporting the outcomes of lens-based refractive surgery.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Michael Patterson, DO, discusses Johnson & Johnson’s OptiBlue violet light-filtering technology for multifocal IOLs.

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Jay S. Pepose, MD, PhD, discusses advances in pharmacological treatment for reduction of pupil diameter, which may benefit patients with night vision disturbances.

A new AI-based model showed the ability to identify eyes with normal topographies at risk for developing post-LASIK ectasia.

The decision to move to a permanent surgical treatment for presbyopia is an individual choice. It depends on the patient’s exams, their stage of life, the way their eyes are aging and their ultimate goals.

Few visual impairments have as far a reach as presbyopia.

Presbyopia is the second most common refractive error we deal with as ophthalmologists, myopia being No. 1. Approximately 128 million people in the United States and 2 billion people globally have presbyopia.

Orasis Pharmaceuticals has submitted a new drug application to the FDA for CSF-1, its investigational eye drop candidate for presbyopia, according to a press release.